T-cell Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for T-cell Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia [Phase 3]
Phase 3 clinical trial evaluating imatinib mesylate in combination with chemotherapy for newly diagnosed Philadelphia chromosome-positive ac…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia [Phase 1]
This update describes a Phase 1 trial evaluating FLAG chemotherapy in combination with Lisaftoclax and Pelcitoclax for relapsed/refractory T…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: A Study of CTD402 in T-ALL/LBL Patients [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating CTD402 in patients with T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma is currently re…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Venetoclax and Decitabine in R/R T-ALL [Phase 2]
Phase 2 clinical trial of venetoclax and decitabine for relapsed/refractory T-cell acute lymphoblastic leukemia is currently recruiting at S…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia [Phase 2]
A Phase 2 clinical trial evaluating isatuximab for adults with relapsed/refractory CD38-positive T-cell acute lymphoblastic leukemia is curr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating low-intensity chemotherapy plus venetoclax for relapsed or refractory B-cell and T-cell acute lymph…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating combination chemotherapy with nelarabine for T-cell acute lymphoblastic leukemia and T-cell lymphoblasti…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) [Phase 2, Phase 3]
A Phase 2/Phase 3 trial is evaluating adding daratumumab to standard chemotherapy for newly diagnosed T-cell acute lymphoblastic leukemia an…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma [Phase 1]
Phase 1 study evaluating anti-CD7 CAR-T cells in relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoma is currently recruiting…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma [Phase 1]
A Phase 1 trial evaluating Anti-CCR9 CAR T Cells for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma is currently recr…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) [Phase 1]
Phase 1 study of a CD70-targeted chimeric antigen receptor (CAR) T-cell therapy named SEVENTY for acute leukemias; the trial is not yet recr…
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating SupCD7 CAR T-cell therapy for relapsed or refractory CD7-positive hematologic malignancies is cu…
-
CLINICAL_TRIALS research · 2025-12-12Clinical Trial Update: To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT [Phase 1]
A Phase 1 clinical trial is evaluating CD7-targeted CAR-T therapy for patients with MRD-positive T-cell acute lymphoblastic leukemia or lymp…
-
CLINICAL_TRIALS trial_result · 2025-12-05Clinical Trial Update: Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas [Phase 2]
Phase 2 trial evaluating low-dose chidamide as maintenance therapy after allogeneic hematopoietic stem cell transplantation in T-cell acute …
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma [Phase 2]
PA3-17 is being evaluated in a Phase 2 trial for adults with CD7-positive relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL [Phase 1, Phase 2]
An ongoing Phase 1/2 pediatric trial evaluating CD7-targeted CAR-T cells for relapsed/refractory CD7-positive T-cell acute lymphoblastic leu…
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation [Phase 2]
A Phase 2 clinical trial is evaluating the feasibility and safety of donor-derived natural killer cell infusions to prevent leukemia relapse…
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL [Phase 2]
Phase II trial evaluating the safety and efficacy of CB-103 in combination with Venetoclax for relapsed/refractory T-cell acute lymphoblasti…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies [Phase 1, Phase 2]
A multicenter Phase 1/2 open-label, single-arm study evaluating nanobody-based CD5-CAR T cell therapy for relapsed/refractory T-cell maligna…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating autologous and donor-derived CD7 CAR-T cell therapy for refractory or relapsed T-cell malignancies,…
-
CLINICAL_TRIALS research · 2025-10-23Clinical Trial Update: Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells [Phase 1]
A Phase 1 clinical trial evaluates CD7-targeted CAR-T cells derived from autologous T cells for high-risk T-cell malignancies and is current…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL [Phase 3]
A Phase 3 clinical trial evaluating targeted drugs combined with chemotherapy for T-cell acute lymphoblastic leukemia is currently recruitin…
-
CLINICAL_TRIALS other · 2025-10-01Clinical Trial Update: Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy [Phase 2]
Phase 2 trial evaluating daratumumab for adults with MRD-positive T-cell acute lymphoblastic leukemia after standard chemotherapy; the study…
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL [Phase 1]
This report summarizes the completion of a Phase 1 study of WU-CART-007, an allogeneic anti-CD7 CAR-T cell therapy, in patients with relapse…
-
CLINICAL_TRIALS research · 2025-09-04Clinical Trial Update: Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen [Phase 1]
Phase 1 trial evaluating autologous CD5-targeted CAR T cells for T-cell malignancies expressing CD5, currently recruiting.